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Cryptococcus neoformans is an encapsulated
fungal organism (Figure 1) that can cause disease
in apparently immunocompetent, as well as
immunocompromised, hosts (1,2). Most suscep-
tible to infection are patients with T-cell
deficiencies (1,2). C. neoformans var. neoformans
causes most cryptococcal infections in humans, so
this review will focus on information from the
neoformans variety of this basidiomycetous
fungus.  C. neoformans var. neoformans is found
worldwide; its main habitats are debris around
pigeon roosts and soil contaminated with decaying
pigeon or chicken droppings (1,3). Not part of the
normal microbial flora of humans, C. neoformans
is only transiently isolated from persons with no
pathologic features (2,4). It is generally accepted
that the organism enters the host by the
respiratory route in the form of a dehydrated
haploid yeast or as basidiospores. After some
time in the lungs, the organism hematogenously
spreads to extrapulmonary tissues; since it has a
predilection for the brain, infected persons
usually contract meningoencephalitis (1). If
untreated, cryptococcal meningoencephalitis is
100% fatal, and even when treated with the most
effective antifungal drugs, cryptococcal infec-
tions can be fatal if the host does not have
adequate T-cell-dependent immune function (2).
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Life-threatening infections caused by the encapsulated fungal pathogen
Cryptococcus neoformans have been increasing steadily over the past 10 years
because of the onset of  AIDS and the expanded use of immunosuppressive drugs.
Intricate host-organism interactions make the full understanding of pathogenicity and
virulence of C. neoformans difficult. We discuss the current knowledge of the
characteristics  C. neoformans must possess to enter the host and establish progressive
disease: basic growth requirements and virulence factors, such as the polysaccharide
capsule; shed products of the organism; melanin production; mannitol secretion;
superoxide dismutase; proteases; and phospholipases.
Figure 1. Transmission electron micrograph of
budding  C. neoformans showing the characteristic
polysaccharide capsule.72 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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To be classified as a pathogen, an organism
must be able to cause infection under certain
conditions. By this definition, C. neoformans can
certainly be classified as a pathogen. Because the
immunodeficient are more susceptible than the
immunocompetent to infection with this yeast-
like organism, C. neoformans is frequently
referred to as an opportunistic pathogen. The
factors that make C. neoformans a pathogen can
be divided into two major groups. The first
comprises the basic characteristics needed to
establish an infection and survive in the human
host; the second comprises the virulence factors
that affect the degree of pathogenicity.
Basic Characteristics for Pathogenicity
The Infectious Particle
To enter the alveolar spaces of the lungs and
establish pulmonary infection, an organism must
produce viable forms smaller than 4 mm in
diameter. The typical vegetative form of C.
neoformans is the yeast form with a cell diameter
of 2.5 mm to 10 mm. The organism can also
undergo sexual reproduction, and since it is a
basidiomycete (Filobasidiella neoformans), it
forms basidiospores. Sexual reproduction ap-
pears to occur much less frequently in nature
than asexual or vegetative reproduction. The
sexual spores (basidiospores) are approximately
1.8 mm to 3 mm in diameter and result from crosses
of the a- and a-mating types on an appropriate
medium (1). Although the exact nature of the
infectious particles of C. neoformans is not
known, they are presumed to be the dehydrated
yeast cells or basidiospores of the appropriate
size range to get into the lungs. Once inside the
lungs, the yeast cells become rehydrated and
acquire the characteristic polysaccharide capsule
(Figure 2). In the case of basidiospores, they
would convert to encapsulated blastoconidia.
Recently, Wickes et al. (5) reported that the
a-mating type of C. neoformans can produce
monokaryotic hyphae on a solid medium without
a nitrogen source or water. The monokaryotic
hyphae contain clamp connections and basidia
with short chains of basidiospores and are similar
in all respects except in nuclei number to the
dikaryotic hyphae of the sexual forms (5). The
haploid fruiting bodies formed by nitrogen-starved
a-mating type isolates also produce abundant
amounts of blastoconidia, which on the appropri-
ate medium can produce haploid hyphae (5).
None of the a-mating type strains tested
produced the haploid fruiting bodies. Backcross
studies indicated that the ability to undergo
haploid fruiting lies within (or is tightly linked to)
the MATa locus, which is responsible for the a-
mating type phenotype (5). These results suggest
basidiospores from the monokaryotic hyphae
may be another source of the infectious particle in
nature. Regardless of the nature of the infectious
particle (yeast cell or basidiospore), if a cryptococcal
isolate is not able to produce small infectious
particles, it cannot be pathogenic under the usual
conditions for establishing the disease.
Mating Types
Kwon-Chung and Bennett (6) surveyed the
mating types of C. neoformans isolates from
environmental and clinical sources and found a
30- to 40-fold higher frequency of a-mating type
than a-mating type. The skewed ratio of a-mating
type to a-mating type was not thought to be due to
a genetic preponderance towards a-mating type
progeny because crosses between two test strains
resulted in a 1:1 ratio of a-mating and a-mating
type progeny (7). To examine the reason for the
disparate ratio, Kwon-Chung and colleagues (8)
constructed a pair of congenic strains of C.
neoformans that differed only in their mating
type. Survival studies with these congenic strains
demonstrated that the a-mating type (B-4500)
was significantly more virulent than the a-
mating strain (B-4476) when injected intrave-
nously into mice (8). Eighty percent of mice
infected with 106 B-4500 (a-mating type) were
Figure 2. Proposed means of infection by C.
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dead within 36 days; whereas, it took 93 days for
80% of mice infected with 106 B-4476 (a-mating
type) to die (8). Although the mating type locus
of  C. neoformans has been cloned and partially
characterized, the genes or gene products that
contribute to the increased virulence of
a-mating type isolates are not known.
The mating type locus (MATa) cloned from an
a-mating type C. neoformans isolate is 35 kb to 45
kb long (9). Moore and Edman (9) demonstrated
that introducing a 2.1-kb fragment of the MATa
locus into an a-mating strain isolate stimulated
filament formation on starvation medium.
Basidia and basidiospores were not produced on
the filaments. In contrast, electroporation of an
a-mating strain with the same MATa DNA
fragment was ineffective in stimulating filament
formation under the same growth conditions (9).
Sequence analysis of the 2.1-kb fragment from
the MATa locus identified a 114-bp open reading
frame that encodes a 38-amino acid propheromone
peptide (9). The nature and the effects of the
active pheromone peptide on mating and possibly
virulence of C. neoformans are unknown;
consequently, how the mating type relates to
virulence at the genetic level is also unknown.
However, the observation of haploid fruiting by
a-mating type isolates of C. neoformans on
nitrogen- and water-depleted medium (5) may
help explain why the a-mating type isolates from
clinical specimens are more frequent than the
a-mating type strains (6).
Growth In Vivo
To cause infection in humans, a C.
neoformans isolate must grow at 37oC in an
atmosphere of approximately 5% CO2 and at a pH
of 7.3 to 7.4. To survive at 37oC, the organism
must have an intact gene that encodes the C.
neoformans calcineurin A catalytic subunit (10).
Calcineurin is a serine-threonine specific phos-
phatase that is activated by Ca2+-calmodulin and
is involved in stress responses in yeasts (10).
Although calcineurin A mutant strains of C.
neoformans can grow at 24oC, they cannot survive
in vitro at 37oC, in 5% CO2, or at alkaline pH (10).
Since these are similar to conditions in the host,
one would predict that the calcineurin A mutant
would not survive in the human host. In support
of that prediction, Odom et al. have shown that
such mutants are not pathogenic for immunosup-
pressed rabbits (10). Calcineurin A appears to be
a basic requirement for C. neoformans survival in
the host and consequently is a necessary factor
for the pathogenicity of the organism.
Virulence Factors
Virulence factors increase the degree of
pathogenicity of a microbe. C. neoformans has a
number of virulence factors; generally, the
virulence of an isolate cannot be attributed to any
single factor, but rather it is attributed to many
working in unison to cause progressive disease.
As virulence factors go, those of C. neoformans
would be considered low-grade. We will discuss
each virulence factor separately; however, the
severity of the host’s disease results from a
combination of several virulence factors superim-
posed on the host’s innate and immune resistance
status. The virulence factors that will be discussed
are capsule, cryptococcal products, melanin
production, mannitol production, and potential
factors such as superoxide dismutase, proteases,
phospholipase B, and lysophospholipase. The
polysaccharide capsule and the soluble extracellu-
lar constituents of C. neoformans (referred to here
as cryptococcal products) are probably the
dominant virulence factors.
Capsule
C. neoformans has a capsule composed
primarily of a high molecular weight polysaccha-
ride that has a backbone of a-1,3-D-mannopyranose
units with single residues of ß-D-xylopyranosyl and
ß-D-glucuronopyranosyl attached (11-15). This polysac-
charide is referred to as glucuronoxylomannan (GXM)
(11) and has four serotypes: A and D, produced by C.
neoformans var. neoformans, and B and C,
produced by C. neoformans var. gattii. The evidence
indicates that the capsule is a key virulence factor
for C. neoformans; acapsular mutants are typically
avirulent, whereas encapsulated isolates have
varying degrees of virulence (16-19). Two capsular
genes, CAP59 and CAP64, have been described (20-
22). Complementation of an acapsular, avirulent
mutant with CAP59 resulted in a virulent
transformant with a capsular phenotype, and
deletion of CAP59 by homologous integration
caused the encapsulated organism to become
acapsular and avirulent (20). Similar observations
have been made with the CAP64 gene (21,22).
Although their biochemical functions have not been
defined, it appears that the two genes are essential
for capsule formation and virulence.74 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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Chemotactic Effects on Leukocytes
Some properties of the C. neoformans capsule
enable the host to more effectively clear the
organism from tissues; however, others protect
the organism from host defenses. The capsules of
serotype A and D isolates are chemotactic for
neutrophils (23). Moreover, complement is fixed
by cryptococcal capsules by the alternative
pathway (24), and this process produces
chemotactic peptides such as C5a (23). Chemot-
axis of leukocytes induced by either of these
mechanisms would be advantageous to the host.
Effects of Complement Interactions
Complement fixing by C. neoformans in
tissue would result in chemotactic factor
production and attraction of leukocytes into the
infection site. Once in the infected tissue, the
leukocytes would interact with and kill the
organism. As complement is fixed, C3b and C3bi
are deposited on the surface of the cryptococci
(24). The capsule can mask the C3b and C3bi
deposits (24-26); however, if they are not completely
masked, the deposited complement components
facilitate binding of the cryptococci to CR3
receptors on leukocytes (27). Such binding
interactions are advantageous to the host; they
enhance the opportunity for the leukocytes to kill
the cryptococci either extracellularly or after
phagocytosis. The organism can also be opsonized
by antibodies to GXM, but the capsule may block
the Fc portion of the antibody and prevent it from
binding to Fc receptors on the phagocytic host cells
(28). Some of these functions of the capsule favor the
host; however, if the capsule is very large, the
organism is protected (24-26). The cryptococci could
deplete complement in the host, creating an
environment that favors the cryptococci (29).
Effects on Phagocytosis
All considered, the capsule is more beneficial
to the organism than to the host. Encapsulated C.
neoformans cells are not phagocytized or killed by
neutrophils, monocytes, or macrophages to the
same degree as acapsular mutants (25,30-33).
Encapsulated C. neoformans have a stronger
negatively  charged surface than acapsular cells or
Saccharomyces cerevisiae cells (34). The high
negative charge could cause electrostatic repul-
sion between the organism and the negatively
charged host effector cells and reduce intimate
cell-cell interactions required for clearance of
the cryptococci (34).
Altered Antigen Presentation
The inability of macrophages to ingest the
encapsulated organisms could also diminish
antigen presentation to T cells and consequently
reduce immune responses. This speculation has
been experimentally demonstrated by Collins
and Bancroft (35). Other studies with human
alveolar macrophages have confirmed that antigen
presentation is not as effective with encapsulated
cryptococci as with acapsular strains (33,36).
Unlike acapsular cells, encapsulated isolates
cannot stimulate proliferative responses in T cells
because of the reduced secretion of interleukin-1
(IL-1) by the antigen-presenting cells stimulated
with the encapsulated yeasts (36).
Effects on Cytokine Production
In addition to being antiphagocytic, more
resistant to killing, and less able to stimulate T-
cell proliferation (25,30-33,35,36), highly encap-
sulated isolates of C. neoformans opsonized with
a heat-labile serum component, presumably
complement, do not stimulate monocytes and
macrophages to produce proinflammatory
cytokines such as TNFa, IL-1ß, and IL-6 as
effectively as similarly opsonized nonencapsulated
or weakly encapsulated isolates (37-41). The
signal for induction of cytokine production can be
a direct result of the attachment of the monocyte
or macrophage to the acapsular cryptococci or can
be an outcome of the phagocytic process, induced
by acapsular cryptococci. Since the capsule blocks
phagocytosis, any cytokines induced by the
phagocytic process would not be induced by the
encapsulated C. neoformans cells. If the cryptococ-
cal cell wall materials must be exposed to induce
cytokine production, the capsule would block the
direct induction of cytokine production. Regard-
less of the mechanism of stimulation, the lack of
production of proinflammatory cytokines could
have a bearing on protection. TNFa is necessary
for the induction of the protective immune
response against C. neoformans (42). Conse-
quently, the lack of or reduced production of
TNFa in infections with highly encapsulated
isolates of C. neoformans would prevent the
induction of protective immunity, resulting in
progressive disease. The roles of IL-1ß and IL-6 in
protecting against C. neoformans have not been
defined, but it is highly probable that the lack of
these two cytokines could compromise the
protective responses of the host and give
cryptococci the advantage.75 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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In contrast to the reduced TNFa, IL-1ß, and
IL-6 produced by stimulating monocytes and
macrophages with highly encapsulated crypto-
cocci, IL-10 produced by these host cells increases
after interaction with encapsulated strains (43).
Neutralization of IL-10 with anti-IL-10 in
cocultures of human peripheral blood mono-
nuclear cells and encapsulated cryptococci
increased the amounts of TNFa and IL-1ß
produced, which indicates that the induction of
IL-10 production by stimulating macrophages
with encapsulated C. neoformans downregulates
the production of the proinflammatory cytokines
TNFa and IL-1ß (43). One might predict that the
induction of high levels of IL-10 would also
preferentially stimulate the induction of a T-
helper 2 (Th2) response rather than a Th1
response in the T cells (44). Since the Th1
response is associated with protection against
C. neoformans (45), increased levels of IL-10
would dampen induction of the protective
immune response.
Encapsulated cryptococcal cells do not affect
the different types of leukocytes in the same
manner. Although encapsulated isolates do not
stimulate macrophages to produce proinflammatory
cytokines, they do stimulate neutrophils to
produce proinflammatory cytokines and the
chemotactic factor IL-8 more effectively than
weakly encapsulated or acapsular organisms
(46). As with the stimulation of macrophages by
acapsular cryptococci to produce proinflammatory
cytokines, serum is required for the encapsulated
organisms to induce neutrophils to produce
cytokines (46). In the case of cytokine production
by neutrophils in response to encapsulated C.
neoformans, it appears that the opsonization
process releases a factor into the supernatant
that induces the neutrophils to produce the
cytokines (46). How these opposing in vitro
observations with macrophages and neutro-
phils relate to the in vivo system or
pathogenicity is yet to be determined.
Cryptococcal Products
In disseminated cryptococcosis, measurable
levels of cryptococcal products are present in the
body fluids of the patients (47). Although GXM is
the major cryptococcal component in body fluids,
it is highly probable that the organism also sheds
galactoxylomannan (GalXM) and mannoproteins
(MP) in vivo. This speculation is based on indirect
evidence from in vivo studies and on the fact that
GalXM and MP are in culture medium when the
organism is grown in vitro (15,48). Cryptococcal
antigens in serum or spinal fluid are diagnostic
for cryptococcosis (47). Furthermore, if dissemi-
nated cryptococcosis patients have high crypto-
coccal antigen titers at the onset of therapy, they
are less likely to respond to therapy or more likely
to die before therapy is completed than patients
with low cryptococcal antigen titers (49). The
direct relationship of cryptococcal antigen levels
in body fluids and the severity of disease suggests
that the cryptococcal antigens in the host’s
circulatory system or spinal fluid may have
adverse effects on host defenses.
Effects on Leukocyte Migration
It has been recently demonstrated in the
mouse model that intravascular cryptococcal
antigens inhibit the migration of leukocytes from
the bloodstream into an inflammatory site (50).
Intravascular cryptococcal antigens significantly
reduce leukocyte infiltration into a site of acute
inflammation induced by such stimuli as
cryptococcal culture filtrate antigen, TNFa, or
the chemotactic peptide FMLP (formylmethionyl
leucyl phenylalanine) or into a delayed-type
hypersensitivity reaction site induced by purified
protein derivative of Mycobacterium tuberculosis
or by C. neoformans antigen(s) (50). Each of the
identified cryptococcal products, GXM, GalXM,
and MP, when given intravenously to mice, can
inhibit leukocyte migration (50). Considering that
GXM is the dominant cryptococcal component in
the host’s circulation, one might predict that
GXM is mainly responsible for the reduced
leukocyte migration into inflammatory sites (50).
These observations imply that pulmonary
cryptococcosis patients, who have low to no
cryptococcal antigen concentrations in their
serum, would have a normal influx of leukocytes
into pulmonary sites of infections. On the other
hand, in severe pulmonary infections or in
disseminated cryptococcosis patients who have
high levels of circulating cryptococcal antigens,
minimal inflammation would be expected in the
infected tissues. In fact, for years investigators
have commented on the minimal host tissue
responses observed in patients with disseminated
cryptococcosis (3).  These recent data demonstrate
that the circulating cryptococcal antigens are
responsible, at least in part, for the lack of host
tissue response.76 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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Cryptococcal antigen(s) can potentially pre-
vent leukocytes from migrating into an inflam-
matory site in two nonexclusive ways (51,52).
First, GXM can stimulate neutrophils to shed
L-selectin, a surface molecule necessary for the
first step in neutrophil movement into tissues
(51). Without L-selectin the neutrophils do not
slow down and roll along the inflamed endothelial
cells lining the blood vessels. With this first step
in extravasation blocked, the numbers of
neutrophils in infected tissues would be greatly
reduced. Second, GXM and GalXM can bind to
CD18, the beta chain of the adhesion molecule
LFA-1, and prevent the binding of anti-CD18 to
LFA-1 (52). Consequently, this binding of GXM
and GalXM could prevent LFA-1 on the neutrophils
from binding to the LFA-1 ligand, ICAM-1 on the
inflamed endothelial cell surface. If leukocytes are
inhibited from entering tissues by either or both of
these mechanisms, the organism is not effectively
eliminated, and the disease is more severe.
Induction of Immunomodulatory Cells
Cryptococcal antigens injected into the
bloodstream of experimental animals can induce
regulatory T cells, which dampen or ablate the
anticryptococcal humoral as well as cell-
mediated immune responses (53-71). Some
clinical correlates support the concept that the
antigenemia seen in disseminated cryptococcosis
downmodulates the immune responses (72,73).
A long-lasting, specific immunologic unre-
sponsiveness has been reported in persons cured
of cryptococcal meningitis (72-74). Although they
made antipneumococcal polysaccharide antibod-
ies to the same degree as control volunteers after
vaccination with pneumococcal polysaccharide,
cured patients could not make antibodies to
cryptococcal polysaccharides after vaccination
with cryptococcal antigens (72,73). Henderson et
al. (72,73) speculated that the intense, prolonged
antigenemia associated with the cryptococcosis
may account for the observed unresponsiveness.
It is not unusual for patients with disseminated
cryptococcosis to have depressed cell-mediated
immune (CMI) responses to cryptococcal anti-
gens (75,76). However, sufficient information is
not available to determine whether the patients
had a generalized defect in CMI function or had a
specifically depressed CMI response because of
the cryptococcal antigenemia.
Experimental animal models demonstrate
convincingly that cryptococcal antigens given
intravenously can induce immunoregulatory T
cells that downmodulate the anticryptococcal
CMI response (56-71). Serum from C. neoformans-
infected mice with a cryptococcal antigen titer of
10-4 when transferred intravenously to naive
mice induces regulatory T cells that specifically
depress the anticryptococcal CMI response (67).
Similar immunoregulatory T cells are induced by
simulating the antigenemia with intravenous
injection of cryptococcal culture filtrate antigen
(56,57,60-63,66-69). The immunoregulatory CD4+
T cells, which appear in the lymph nodes of the
mice 7 days after antigen injection, diminish the
induction of T cells responsible for the
anticryptococcal delayed-type hypersensitivity
response and reduce the ability of the mice to
clear cryptococci from tissues (56,57,60,68). A
second immunoregulatory T cell, a CD8+ cell, has
been found in spleens of mice (57). The CD4+
immunoregulatory cells do not alter the numbers
or types of leukocytes that infiltrate an
anticryptococcal delayed-type hypersensitivity
reaction; however, they do have a downregulating
effect on IL-2 and IFNg production at the site (77).
In contrast, the CD8+ immunoregulatory cells
appear to affect the numbers of neutrophils that
infiltrate the delayed-type hypersensitivity
reaction site (Murphy, unpub. data). The details
of the characteristics and functions of these
immunoregulatory T cells have been reviewed
(45). The available data strongly support the
notion that cryptococcal products in the
circulation induce an array of immunoregulatory
T cells, which depress the anticryptococcal
immune responses and protection.
More consideration should be given to the
impact of high levels of cryptococcal antigen in
the cerebrospinal fluid (CSF) on progression of
disease. As suggested by Denning et al. (78), high
cryptococcal antigen concentrations could change
the osmolality of the CSF, thereby affecting its
outflow and adsorption and increasing intracra-
nial pressure. The increased pressure may cause
headaches, visual loss, and early death (78). It is
also possible that release of mannitol by C.
neoformans contributes to increased intracranial
pressure in cryptococcal meningitis patients (78).
Melanin Synthesis
One characteristic that differentiates patho-
genic isolates of C. neoformans from nonpatho-
genic isolates and other Cryptococcus species is
the organism’s ability to form a brown to black77 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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pigment on a medium (such as birdseed or caffeic
acid agar) that contains diphenolic compounds
(1). This pigment, first described by Staib (79), is
a melaninlike compound produced by C. neoformans
isolates with phenoloxidase activity (80). The
importance of melanin production in C. neoformans
virulence was first demonstrated in the early
1980s. Rhodes, Polacheck, and Kwon-Chung (81)
reported that naturally occurring C. neoformans
mutants lacking melanin (Mel-) were less
virulent in mice than melanin-producing strains.
Others (82-84), using chemically induced mu-
tants or isogenic pairs of C. neoformans, have
confirmed and extended this observation.
Biochemical analyses suggest that in C.
neoformans melanogenesis is accomplished by
conversion of dihydroxyphenols such as 3,4-
dihydroxyphenylalanine (DOPA) to dopaquinone
(Figure 3). This conversion is catalyzed by a
phenoloxidase and is the rate-limiting step,
presumably because subsequent steps in the
pathway, such as dopaquinone rearranging to
dopachrome and ultimately autoxidation to
melanin, are spontaneous (85). C. neoformans
lacks a tyrosinase enzyme required for endog-
enous production of dihydroxyphenols (83); thus
to produce melanin, a C. neoformans isolate must
be able to acquire diphenolic compounds from its
growth environment, and it must have the
enzyme phenoloxidase to catalyze conversion of
these compounds into the subsequent melanin
intermediates. The brain is a tissue rich in
catecholamines such as DOPA and is a favorite
target for infection by C. neoformans. However,
the organism cannot use catecholamines as a sole
carbon source, which suggests that the brain is
not a preferred nutritional niche for growth of
C. neoformans (86); rather, it may serve as a
survival niche as described below.
Polacheck et al. (86) reported that melanin-
producing isolates of C. neoformans were
resistant to damage by an in vitro epinephrine
oxidative system, whereas mutants lacking
phenoloxidase activity were highly susceptible,
as evidenced by decreased survival. Jacobson
and Tinnell (87) found that melanin protected
C. neoformans from damage by hypochlorite and
permanganate but not by hydrogen peroxide. In
these experiments, hypochlorite was 100 times
more fungicidal than hydrogen peroxide, and
C. neoformans could produce sufficient levels of
melanin to effectively protect the organism from
oxidative compounds produced by macrophages
(87). Wang and Casadevall (88) extended these
findings by examining survival of C. neoformans
in the presence of nitric oxide and reactive nitrogen
intermediates as well as in the epinephrine
oxidative system described by Polacheck et al. (86).
Wang and Casadevall cultured C. neoformans cells
with L-DOPA to melanize the yeast cells (88).
Melanized cryptococci survived damage by both
nitrogen- and oxygen-derived oxidants signifi-
cantly better than nonmelanized organisms of
the same strain. These results support the
hypothesis that C. neoformans uses catechola-
mines in the brain to make melanin, thereby
protecting the organism from oxidative damage
by scavenging free radicals (86).
Recently, cryptococcal diphenoloxidase has
been purified, and the gene CNLAC1 encoding
this enzyme was cloned (89). The glycosylated
protein has a molecular weight of 75 kDa and
contains copper. The substrate specificity of the
enzyme indicates that it is a laccase. CNLAC1
contains 14 introns, a 624 amino acid open
reading frame; transcriptional activity is dere-
pressed in the absence of glucose (89), which
confirms an earlier report of low glucose
requirements for melanin formation (90). Disrup-
tion of CNLAC1 resulted in loss of virulence of
C. neoformans, whereas complementation with
CNLAC1 increased virulence of Mel- mutants in
mice (84); these results suggest that the laccase
(phenoloxidase) encoded by CNLAC1 is a potential
virulence factor of C. neoformans. Furthermore,
transcripts of the CNLAC1 gene have been
detected by reverse transcription-polymerase
chain reaction (RT-PCR) in C. neoformans yeast
cells isolated from CSF in a rabbit model of
cryptococcal meningitis (84).
Figure 3. Proposed pathway for melanin synthesis by
C. neoformans (85).78 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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Besides acting as an antioxidant, melanin
production may help C. neoformans survive in
the host in other ways. Melanized yeast cells are
less susceptible to amphotericin B than
nonmelanized yeast cells, and this may contrib-
ute to the inability to effectively treat infections
in immunocompromised hosts (91). Furthermore,
phagocytosis of melanized C. neoformans by a
macrophage cell line in the presence of an anti-
GXM antibody was decreased, which suggests
that melanin deposition in the cell wall may
inhibit opsonization by specific antibodies (92).
Recently, Huffnagle and coinvestigators (93)
reported that melanized heat-killed C. neoformans
strain 145 yeast cells stimulated less TNFa
production by alveolar macrophages and less
antigen-specific T-cell proliferation than
nonmelanized heat-killed 145 strain cells. The
authors suggest that melanin “cloaks” C. neoformans
from recognition by host effector cells and
inhibits induction of a protective T-cell-mediated
immune response (93); however, it is possible
that scavenging of host-produced oxidants and
inhibition of phagocytosis by melanin may
contribute to the decreased TNFa production and
lymphoproliferation observed.
Although melanin production is important in
the virulence of C. neoformans, there is very little
evidence demonstrating the presence of melanin
in vivo. One report indicates that phenoloxidase
activity in C. neoformans is greatly diminished at
37oC compared with activity at 25oC, which
suggests that melanin production may be limited
in vivo (94). Detection of melanin in vivo is
hampered by the lack of specific antibodies or
stains. A modified Fontana-Masson stain has
been used to detect a brown pigment in the cell
wall of C. neoformans cells in histologic brain
sections; however, the stain is not specific
because  Cryptococcus laurentii, which is Mel-,
also stains with Fontana-Masson (95).
In summary, accumulating evidence indi-
cates that melanin production is an effective
survival (virulence) factor of C. neoformans, and
melanin may serve multiple roles in protecting
this medically important fungus from host
defenses. Two caveats should be noted in labeling
melanin as a major virulence factor for C.
neoformans. The C. neoformans isolate must be
able to internalize the melanin precursors, and
the phenoloxidase enzyme must make a
sufficient amount of melanin precursor at 37oC.
Consequently, much more work is needed to
delineate the role of melanin production in
virulence of C. neoformans, especially in light of
the apparent temperature sensitivity of the
cryptococcal phenoloxidase enzyme.
Mannitol Production
Accumulating evidence suggests that produc-
tion of the hexitol D-mannitol may contribute to
survival of C. neoformans in the host. Wong et
al. (96) reported that of the 12 human isolates
of  C. neoformans examined, all produced and
secreted D-mannitol into growth medium.
Further, by using a rabbit cryptococcal meningi-
tis model, they showed that C. neoformans can
produce D-mannitol in vivo. CSF from rabbits
treated with cortisone and infected intracister-
nally with C. neoformans contained more D-
mannitol than CSF from controls, cortisone-
treated uninfected rabbits, or rabbits infected
with  C. neoformans but not treated with cortisone
(96). In the latter group, cryptococcal infection
was limited. The levels of D-mannitol in infected
rabbit CSF correlated well with both the numbers
of culturable C. neoformans and the cryptococcal
antigen titer of the CSF, which suggests that
levels of D-mannitol in CSF may be prognostic
(96); however, it is not known whether different
isolates of C. neoformans vary in mannitol
production. These authors suggested two means
by which mannitol production may contribute to
C. neoformans pathogenesis. First, high concen-
trations of D-mannitol in the CNS may contribute
to brain edema. Second, mannitol is a potent
scavenger of hydroxyl radicals, and cryptococcal-
produced D-mannitol may help protect the
organism from oxidative damage (96).
To investigate the role of mannitol in
cryptococcosis, Chaturvedi and co-workers (97)
isolated a low mannitol producing mutant after
UV irradiation of C. neoformans strain H99. The
mutant, mannitol low producer (MLP), was
similar to the parent strain H99 in many growth
and morphology characteristics and in known
virulence factors such as capsule production and
phenoloxidase activity (97). However, the mutant
MLP strain was more susceptible to growth
inhibition and killing by heat and high salt than
the parent strain. In addition, the mutant MLP
strain was significantly less virulent than the
parent strain (MLP LD50 = 3.7 X 106 CFU, H99
LD50 = 6.9 X 102) (97). Further comparisons of H99
and MLP strains showed that polymorphonuclear
leukocytes (PMNL) killed MLP significantly79 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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better than H99 at several effector-to-target
ratios (98). Addition of superoxide dismutase,
mannitol, or dimethyl sulfoxide inhibited PMNL
killing of both strains, but addition of catalase did
not alter killing, which suggests that reactive
oxygen intermediates such as the hydroxyl
radical and hypochlorous acid are potent effector
molecules against C. neoformans and mannitol
may protect against oxidative killing by
scavenging such compounds (98).
The results above indicate that mannitol
production by C. neoformans correlates with
increased resistance to heat stress, osmotic
stress, and damage by reactive oxygen intermedi-
ates, as well as increased pathogenicity of this
fungal agent. Additional studies are required to
determine the role of mannitol production in
virulence of C. neoformans. Isogenic strains
lacking the enzyme required for mannitol
production, namely mannitol dehydrogenase, are
not available because the gene for this enzyme
has not been found. However, a gene (Mtl) has
been isolated from C. neoformans that can induce
expression of the S. cerevisiae mannitol dehydro-
genase gene (99). The 346 amino acid product
encoded by the Mtl gene is thought to be involved
in regulating mannitol production in C. neoformans
and may be beneficial in future studies of
mannitol production (99).
Other Potential Virulence Factors
Superoxide Dismutase
Jacobson and coinvestigators (100) exam-
ined superoxide dismutase (SOD) production
by C. neoformans to determine whether SOD
levels increased at 37oC to compensate for possible
decreases in melanin production at this tempera-
ture. These investigators observed an increase in
SOD levels at 37oC, which suggests that SOD may
participate in free radical scavenging at this higher
temperature in vivo (100); however, there is no
evidence that SOD production serves as a virulence
factor for C. neoformans.
Proteases
Muller and Sethi (101) reported that C.
neoformans grown in culture produced a protease
that could digest human plasma proteins, and
Brueske (102) reported that C. neoformans
culture supernatants contained a protease capable
of digesting casein. However, neither of these
studies determined whether the proteases were
manufactured in vivo. Limited evidence indicat-
ing in vivo production of proteases has been
presented by Salkowski and Balish (103). These
investigators observed skin lesions on T-cell–
deficient mice after intravenous infections with
C. neoformans strain SLHA (103). Microscopic
examination of the lesions suggested that the
cryptococcal yeast cells were degrading collagen
bundles in the dermis (103). Supernatants of
SLHA strain cultures liquefied gelatin in vitro
indicating that this cryptococcal strain secreted a
collagenaselike protein (103). Thus, C. neoformans
proteases possibly serve as virulence mecha-
nisms by initiating invasion of host tissues;
however, more studies with isogenic strains of
C. neoformans are required before proteases
can be listed as virulence factors.
Phospholipases
Recently, Chen and co-workers (104,105)
reported phospholipase, lysophospholipase,
and lysophospholipase-transacylase activity of
C. neoformans grown on egg yolk agar. Of 50
strains tested, 49 had phospholipase activity
(104), due to phospholipase B secreted into
cultures (105). Analysis of four strains with
varying levels of phospholipase activity indicated
a correlation between phospholipase activity and
virulence in BALB/c mice (104). The authors
suggest that extracellular phospholipase activity
produced by C. neoformans may disrupt mamma-
lian cell membranes and allow the yeast cells to
penetrate into host tissues (104,105); however,
further investigations are necessary to establish
the role, if any, of these types of products in the
virulence of C. neoformans.
Regulation of Virulence
Regulation of virulence factors such as
capsule production and melanin formation is not
well understood. However, the gene GPA1, which
encodes a G-protein a-subunit, is involved in the
regulation of these virulence factors as well as in
C. neoformans mating (106). Disruption of GPA1
resulted in defects in mating in response to nitrogen
starvation, capsule production in response to iron
limitation, and melanin synthesis in response to
glucose starvation (106). Furthermore, gpa1
mutants were much less virulent in a rabbit
model of cryptococcal meningitis (106). Reconsti-
tution of the gpa1 mutant with wild-type GPA1
restored mating, capsule production, melanin
synthesis, and virulence. Addition of cyclic AMP80 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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also restored these phenotypes, which suggests
that C. neoformans GPA1 regulates these factors
by sensing the nutritional signals of the
environment and regulating cyclic AMP metabo-
lism in the organism (106). These findings along
with results of other molecular studies are
intriguing and represent the initial steps in
defining at the molecular level the factors
controlling virulence in C. neoformans.
Conclusions
Virulent isolates of C. neoformans must be
able to produce small particles that can get into
the alveolar spaces, must be able to grow at 37oC
at a pH of 7.3 to 7.4 in an atmosphere of
approximately 5% CO2, must have an intact
calcineurin pathway, and (possibly) must be an
a-mating type. The ability to produce a large
capsule and shed great amounts of capsular
material into the body fluids makes the
organism highly virulent. Other factors, such
as melanin, mannitol, superoxide dismutase,
protease, and phospholipase production, may
enhance the pathogenicity of C. neoformans.
The effectiveness of many of these cryptococcal
virulence factors depends on the status of the
host’s defensive mechanisms. Although we
have learned much about the pathogenicity and
virulence of C. neoformans, many gaps still
remain in our knowledge.
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